Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Mechanistic modeling to investigate signaling by oncogenic Ras mutants.

Stites EC, Ravichandran KS.

Wiley Interdiscip Rev Syst Biol Med. 2012 Jan-Feb;4(1):117-27. doi: 10.1002/wsbm.156. Epub 2011 Jul 15.

PMID:
21766467
2.

Blocking oncogenic Ras signaling for cancer therapy.

Adjei AA.

J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74. Review.

PMID:
11459867
3.
4.

Mathematical investigation of how oncogenic ras mutants promote ras signaling.

Stites EC, Ravichandran KS.

Methods Mol Biol. 2012;880:69-85. doi: 10.1007/978-1-61779-833-7_5. Review.

PMID:
23361982
5.

Recapitulation of ras oncogene mutations in breast cancer.

Stamatakos M, Stefanaki C, Kontzoglou K, Masouridi S, Sakorafas G, Safioleas M.

Onkologie. 2010;33(10):540-4. doi: 10.1159/000319697. Epub 2010 Sep 20. Review.

PMID:
20926903
6.

Differential oncogenic Ras signaling and senescence in tumor cells.

Bihani T, Mason DX, Jackson TJ, Chen SC, Boettner B, Lin AW.

Cell Cycle. 2004 Sep;3(9):1201-7. Epub 2004 Sep 5.

PMID:
15492501
7.

Oncogenic signaling pathways and deregulated target genes.

Schäfer R, Schramme A, Tchernitsa OI, Sers C.

Recent Results Cancer Res. 2007;176:7-24. Review.

PMID:
17607912
8.

Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine.

Stites EC.

Phys Biol. 2013 Apr;10(2):026004. doi: 10.1088/1478-3975/10/2/026004. Epub 2013 Feb 13.

PMID:
23406820
9.

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Reuter CW, Morgan MA, Bergmann L.

Blood. 2000 Sep 1;96(5):1655-69. Review.

10.

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.

Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. German.

PMID:
12397548
11.

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.

Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M.

Mol Cancer Res. 2007 Feb;5(2):195-201.

12.

Association rate constants of ras-effector interactions are evolutionarily conserved.

Kiel C, Aydin D, Serrano L.

PLoS Comput Biol. 2008 Dec;4(12):e1000245. doi: 10.1371/journal.pcbi.1000245. Epub 2008 Dec 19.

13.

Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.

Karakosta A, Golias Ch, Charalabopoulos A, Peschos D, Batistatou A, Charalabopoulos K.

J Exp Clin Cancer Res. 2005 Dec;24(4):505-14. Review.

PMID:
16471312
14.

Re: Blocking oncogenic Ras signaling for cancer therapy.

Canevari S, Biocca S, Figini M.

J Natl Cancer Inst. 2002 Jul 3;94(13):1031-2; author reply 1032. No abstract available.

PMID:
12096090
15.

Cloning oncogenic ras-regulated genes by differential display.

Jo H, Zhang H, Zhang R, Liang P.

Methods. 1998 Dec;16(4):365-72.

PMID:
10049644
16.

Deciphering the genetic landscape of cancer--from genes to pathways.

Copeland NG, Jenkins NA.

Trends Genet. 2009 Oct;25(10):455-62. doi: 10.1016/j.tig.2009.08.004. Epub 2009 Oct 7. Review.

PMID:
19818523
17.
18.

Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells.

Chi S, Kitanaka C, Noguchi K, Mochizuki T, Nagashima Y, Shirouzu M, Fujita H, Yoshida M, Chen W, Asai A, Himeno M, Yokoyama S, Kuchino Y.

Oncogene. 1999 Apr 1;18(13):2281-90.

19.

Gene expression profile associated with oncogenic ras-induced senescence, cell death, and transforming properties in human cells.

Moumtzi SS, Roberts ML, Joyce T, Evangelidou M, Probert L, Frillingos S, Fotsis T, Pintzas A.

Cancer Invest. 2010 Jul;28(6):563-87. doi: 10.3109/07357900903095623.

PMID:
19883200
20.

Oncogenes are to lose control on signaling following mutation: should we aim off target?

Hornberg JJ, Westerhoff HV.

Mol Biotechnol. 2006 Oct;34(2):109-16.

PMID:
17172656

Supplemental Content

Support Center